

## Michael addition of artemisitene

Xi-Bin Liao, Ji-Ye Han and Ying Li\*

Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road, Shanghai 200031, China

Received 10 November 2000; revised 13 February 2001; accepted 21 February 2001

**Abstract**—Michael addition of artemisitene with triazole, benzotriazole or benzimidazole under non- or base-catalyzed conditions yielded compounds 3a−c and 4a−c. They showed high antimalarial activity against *Plasmodium berghei* in mice. © 2001 Elsevier Science Ltd. All rights reserved.

Artemisinin (Qinghaosu 1), a novel sesquiterpene endoperoxide, is the antimalarial constituent of the Chinese medicinal herb qinghao (Artemisia annua L.).<sup>1</sup> Due to its outstanding antimalarial activity and insolubility in water or oil, a great number of its derivatives and analogues have been synthesized since 1976. 1-5 However, the overwhelming majority of artemisinin derivatives have concentrated on C-12 derivatives, only few C-13 derivatives were prepared.<sup>6-9</sup> Artemisitene 2, another sesquiterpene endoperoxide, exists in the same plant in much lower yield and has less antimalarial activity than artemisinin.  $^{6,10}$  It contains an  $\alpha,\beta$ -unsaturated lactone moiety which can be used as the substrate for some reactions. Recently acid catalyzed Michael additions of artemisitene were published by Ma.<sup>11</sup> We also prepared a new type of C-13 artemisinin derivative by Michael reaction of artemisitene. Here we would like to report their synthesis and antimalarial activity.

According to El-Feraly's procedure, 12 we prepared artemisitene 2 from artemisinin in high vield. It reacted with 1,2,4-triazole, benzotriazole or benzimidazole under different conditions to yield compounds 3a-c and 4a-c. Heating 1,2,4-triazole (as its salt) and 2 in acetonitrile at 60°C gave a mixture of 3a and 4a.13 An aqueous ethanol solution of benzotriazole and 2 was refluxed to yield 3b14 and 4b.15 If the reaction was run in the presence of K<sub>2</sub>CO<sub>3</sub> the yield dropped markedly. Reaction of benzimidazole and 2 in THF in the presence of KF-Al<sub>2</sub>O<sub>3</sub> afforded 3c<sup>16</sup> and 4c<sup>17</sup> smoothly. When 2 reacted with imidazole or morpholine under similar conditions, no product was found. Although the reactions of azoles with  $\alpha,\beta$ -unsaturated ketones usually resulted in mixtures of the triazol-1-yl and 4-yl isomers or benzotriazol-1-yl and 2-yl isomers, 18-20 the formation of no triazol-4-yl and benzotriazol-2-yl isomer was found in our experiments. The addition of these hetero-

0040-4039/01/\$ - see front matter © 2001 Elsevier Science Ltd. All rights reserved. PII: \$0040-4039(01)00310-0

<sup>\*</sup> Corresponding author. Fax: 86-021-64379629; e-mail: yli@mail.shcnc.ac.cn

Compound	Preparation (suspension)	$\mathrm{SD}_{50}~(\mathrm{mg/kg/day})$	$SD_{90} \ (mg/kg/day)$
3a+4a	In water	2.38	6.52
3b	In oil	5.48	11.41
Зс	In water	3.94	10.05
lc	In oil	1.59	56.03
	In water	18.75	56.66
1	In oil	5.13	11.50

Table 1. Antimalarial activity of compounds 3 and 4 against P. bergei K-173 strain in mice (PO)

cyclic compounds to artemisitene led to C-11 diastereoisomers  $3\mathbf{b}/4\mathbf{b}$  and  $3\mathbf{c}/4\mathbf{c}$  which could be separated by column chromatography. The C-11 configuration of 3 and 4 was determined by two-dimensional NOESY spectra. There was a NOESY cross peak between the C-7 H at  $\delta$  1.5 ppm and the C-11 H at  $\delta$  4.0 ppm for  $4\mathbf{b}$ , but no cross peak between these two protons for  $3\mathbf{b}$ . Moreover, the coupling constants between C-11 H and C-7 H in  $4\mathbf{b}$  and  $4\mathbf{c}$  were 4.8 and 5.3 Hz, respectively. While artemisinin 1 and 11-epiartemisinin had  $J_{11,7}$  of 5.4 and 1.2 Hz.8 Hence, the 11-CH<sub>2</sub>R group in 1 and the 11-CH<sub>3</sub> group in 1 should take the same 1-orientation.

The antimalarial activities of compounds 3 and 4 were measured according to Peters'procedure. Mice were infected with  $1.5 \times 10^7$  P. berghei K-173 strain parasitized cells intraperitoneally on day 0. Compounds 3a+4a, 3b, 3c and 4c were ground in water (or peanut oil) and orally administered once a day for  $D_0-D_3$ . The doses of the compounds given were 0.625, 1.25, 2.5, 5 and 10 mg/kg. Blood smears were made on day  $D_4$ , stained, examined under a microscope and calculated by a regression equation. All of the new derivatives tested had antimalarial activity in vivo.

As can be seen from Table 1, the mixture of  $\bf 3a$  and  $\bf 4a$  obviously is the most active with nine times the potency of artemisinin. Compound  $\bf 3b$  showed activity comparable to that of the natural artemisinin. However,  $\bf 3c$  with an  $11\alpha$ -benzimidazolyl group had higher activity than the corresponding  $11\beta$ -isomer  $\bf 4c$ . To our knowledge, this is the first exception to the structure–activity relationship of C-11 substitution in artemisinin.

## Acknowledgements

We are grateful to the State Committee of Science and Technology of China and Chinese Academy of Sciences for financial support and Prof. G.-F. Li (Institute of Microbiology and Epidemiology, Academy of Military Medical Science) for the in vivo antimalarial results reported here.

## References

 China Cooperative Research Group on Qinghaosu and its Derivatives as Antimalarials *J. Trad. Chin. Med.* 1982, 2, 3–8.

- Zaman, S. S.; Sharma, R. P. Heterocycles 1991, 32, 1593–1637.
- Avery, M. A.; Gao, F.; Chong, W. K. M.; Mehrotra, S.; Jennings-White, C. *Trends in Organic Chemistry*; Pergamon Press: Trivandrum, 1993; Vol. 4, pp. 413–468.
- 4. Jung, M. Curr. Med. Chem. 1994, 1, 35-49.
- 5. Wu, Y. L.; Li, Y. Med. Chem. Res. 1995, 5, 569-586.
- Acton, N.; Karle, J. M.; Miller, R. E. J. Med. Chem. 1993, 36, 2552–2557.
- Jung, M.; El-Sohly, H. N.; McChesney, J. D. Synlett 1993, 43–44.
- Avery, M. A.; Gao, F.; Chong, W. K. M.; Mehrotra, S.; Milhous, W. K. J. Med. Chem. 1993, 36, 4264–4275.
- Avery, M. A.; Mehrotra, S.; Johnson, T. L.; Bonk, J. D.; Vroman, J. A.; Miller, R. J. Med. Chem. 1996, 39, 4149–4155.
- Acton, N.; Klayman, D. L. Planta Med. 1985, 51, 441– 442.
- 11. Ma, J. Y.; Weiss, E.; Kyle, D. E.; Ziffer, H. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 1601–1603.
- El-Feraly, F. S.; Ayalp, A.; Al-Yahya, M. A.; McPhail,
   D. R.; McPhail, A. J. Nat. Prod. 1990, 53, 66-71.
- 13. Compounds **3a** and **4a** (1:1): mp 144–146°C. Yield: 40%. 

  <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.20, 8.15 (1H, s, s, azolyl-H), 7.93, 7.90 (1H, s, s, azolyl-H), 5.94, 5.88 (1H, s, s, 5–H), 4.81, 4.73 (1H, m, m, 13–H), 4.48, 4.23 (1H, m, m, 13–H), 3.85, 2.91 (1H, m, m, 11–H), 1.44, 1.41 (3H, s, s, 15–H), 0.96, 0.93 (3H, d, d, J=6.1, 5.8 Hz, 14–H); IR (KBr):  $\nu_{\text{max}}$  1737, 1506, 1400, 1275, 1192, 1119, 880, 845 cm<sup>-1</sup> Anal. calcd for C<sub>17</sub>H<sub>23</sub>N<sub>3</sub>O<sub>5</sub>: C, 58.44; H, 6.63; N 12.03. Found: C, 58.39; H, 6.49; N, 12.00.
- 14. Compound **3b** (11α-isomer): mp 176–178°C. Yield: 40%. 
  <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.06 (1H, d, J=8.5 Hz, arom-H), 7.62 (1H, d, J=8.1 Hz, arom-H), 7.51 (1H, t, J=7.6 Hz, arom-H), 7.38 (1H, t, J=7.9 Hz, arom-H), 5.98 (1H, s, 5-H), 5.20 (1H, d d, J=14.0, 4.5 Hz, 13-H), 5.02 (1H, d d, J=14.0, 10.2 Hz, 13-H), 3.05 (1H, d d, J=10.20, 4.21 Hz, 11-H), 1.47 (3H, s, 15-H), 0.90 (3H, d, J=6.0 Hz, 14-H); IR (KBr):  $\nu_{\rm max}$  1743, 1379, 1269, 1198, 1105, 984, 880, 827 cm<sup>-1</sup>. Anal. calcd for C<sub>21</sub>H<sub>25</sub>N<sub>3</sub>O<sub>5</sub>: C, 63.14; H, 6.31; N, 10.52. Found: C, 63.01; H, 6.40; N, 10.43.
- 15. Compound **4b** (11β-isomer): mp 173–174°C. Yield: 20%. 
  <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.05 (1H, d, J=8.6 Hz, arom-H), 7.60 (1H, d, J=8.3 Hz, arom-H), 7.51 (1H, t, J=7.4 Hz, arom-H), 7.38 (1H, t, J=7.8 Hz, arom-H), 5.93 (1H, s, 5-H), 5.25 (1H, d d, J=14.8, 4.3 Hz, 13-H), 4.89 (1H, dd, J=14.8, 11.3 Hz, 13-H), 3.96 (1H, d t, J=11.2, 4.8 Hz, 11-H), 1.41 (3H, s, 15-H), 0.93 (3H, d, J=6.3 Hz, 14-H); IR (KBr):  $\nu_{\rm max}$  1741, 1454, 1193, 1114, 1002, 880, 850 cm<sup>-1</sup>. Anal. calcd for C<sub>21</sub>H<sub>25</sub>N<sub>3</sub>O<sub>5</sub>: C,

- 63.14; H, 6.31; N, 10.52. Found: C, 63.20; H, 6.30; N, 10.40
- 16. Compound **3c** (11α-isomer): mp 138–140°C. Yield: 26%. 
  <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.02 (1H, s, -N-CH= N-), 7.82 (1H, m, arom-H), 7.49 (1H, m, arom-H), 7.31 (2H, m, arom-H), 5.95 (1H, s, 5-H), 4.84 (1H, d d, J=14.3, 4.9 Hz, 13-H), 4.61 (1H, d d, J=14.3, 10.8 Hz, 13-H), 2.87 (1H, d d, J=10.8, 4.9 Hz, 11-H), 1.49 (3H, s, 15-H), 0.91 (3H, d, J=6.1 Hz, 14-H); IR (KBr):  $\nu_{\rm max}$  1743, 1495, 1379, 1211, 1105, 989, 880, 830, cm<sup>-1</sup>. Anal. calcd for C<sub>22</sub>H<sub>26</sub>N<sub>2</sub>O<sub>5</sub>: C, 66.31; H, 6.58; N, 7.03. Found: C, 66.07; H, 6.73; N, 7.03.
- 17. Compound **4c** (11β-isomer): mp 156–157°C. Yield: 38%. 
  <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.99 (1H, s, -N-CH= N-), 7.80 (1H, m, arom-H), 7.38 (1H, m, arom-H), 7.30 (2H, m, arom-H), 5.89 (1H, s, 5-H), 4.86 (1H, d d,
- J=14.8, 5.8 Hz, 13-H), 4.22 (1H, d d, J=14.8, 8.7 Hz, 13-H), 3.93 (1H, d t, J=9.5, 5.3 Hz, 11-H), 1.40 (3H, s, 15-H), 0.95 (3H, d, J=6.2 Hz, 14-H); IR (KBr):  $\nu_{\rm max}$  1747, 1498, 1290, 1186, 1117, 1002, 974, 883, 830, cm<sup>-1</sup>. Anal. calcd For C<sub>22</sub>H<sub>26</sub>N<sub>2</sub>O<sub>5</sub>: C, 66.31; H, 6.58; N, 7.03. Found: C, 66.25; H, 6.27; N, 6.85.
- Rane, D. F.; Fishman, A. G.; Pike, R. E. Synthesis 1984, 694–695.
- Jähnisch, K.; Seeboth, H.; Krause, E.; Catasus, N. J. Prakt. Chem. 1984, 326, 676–678.
- Takahashi, K.; Shimizu, S.; Ogata, M. Syn. Commun. 1987, 17, 809–815.
- 21. Peters, W. Exp. Parasitol. 1965, 17, 80-89.
- 22. Acton, N.; Klayman, D. Planta Med. 1987, 53, 266-268.
- 23. Wang, D. Y.; Wu, Y. K.; Wu, Y. L.; Li, Y.; Shan, F. J. Chem. Soc., Perkin. Trans. 1 1999, 1827–1831.